Evidence map›Paper›PMID 28105395›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2017

CD44v6-Peptide Functionalized Nanoparticles Selectively Bind to Metastatic Cancer Cells.

Linxian Li, Mark Schmitt, Alexandra Matzke-Ogi, Parvesh Wadhwani, Veronique Orian-Rousseau, Pavel A Levkin

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. CD44v6-Peptide Functionalized Nanoparticles Selectively Bind to Metastatic Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linxian LiInstitute of Toxicology and Genetics Karlsruhe Institute of Technology 76344 Karlsruhe Germany; Institute of Organic Chemistry University of Heidelberg 69120 Heidelberg Germany.
Mark SchmittInstitute of Toxicology and Genetics Karlsruhe Institute of Technology 76344 Karlsruhe Germany.
Alexandra Matzke-OgiInstitute of Toxicology and Genetics Karlsruhe Institute of Technology 76344 Karlsruhe Germany.
Parvesh WadhwaniInstitute of Biological Interfaces (IBG-2) Karlsruhe Institute of Technology 76344 Karlsruhe Germany.
Veronique Orian-RousseauInstitute of Toxicology and Genetics Karlsruhe Institute of Technology 76344 Karlsruhe Germany.
Pavel A LevkinInstitute of Toxicology and Genetics Karlsruhe Institute of Technology 76344 Karlsruhe Germany; Department of Applied Physical Chemistry University of Heidelberg 69120 Heidelberg Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimetastatic activityCD44v6quantum dotstumor targetingv6 peptide

Identifiers

PMID28105395
PMCPMC5238741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.